Company Analysis
Sign in

CRISPR Therapeutics AG (CRSP)

Nasdaq: CRSP · Biological Products, (No Diagnostic Substances) · Zug · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.1
◀ Past 6.0● Present 6.2▶ Future 3.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

77 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to CRISPR Therapeutics AG’s names, not what it holds today.

Patents granted
77
77 utility, 1976 to Dec 31, 2025
Granted in 2025
15
Against 9 in 2024 and 14 in 2023
Applications published
199
21 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology66
Pharmaceuticals4
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
CRISPR THERAPEUTICS AG its own name
named as the applicant on its applications, in CH
0 granted
151 published
CRISPR THERAPEUTICS AG its own name
CH, as the owner printed on each patent. 1 more under the same name are not counted (printed in CN)
77 granted
48 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,427,170Universal donor cellsBiotechnologyCRISPR THERAPEUTICS AG
Aug 5, 202512,378,572Universal donor cellsBiotechnologyCRISPR THERAPEUTICS AG
Jul 22, 202512,365,915Universal donor cellsBiotechnologyCRISPR THERAPEUTICS AG
Jul 1, 202512,344,656Genetically engineered T cells having improved persistence in cultureBiotechnologyCRISPR THERAPEUTICS AG
Jul 1, 202512,344,655Gene-edited natural killer cellsBiotechnologyCRISPR THERAPEUTICS AG
May 20, 202512,304,968T-cells expressing anti-LIV1 chimeric antigen receptorBiotechnologyCRISPR THERAPEUTICS AG
Apr 1, 202512,263,227Optimized mRNA encoding CAS9 for use in LNPsBiotechnologyCRISPR THERAPEUTICS AG
Mar 11, 202512,247,201Materials and methods for treatment of autosomal dominant retinitis pigmentosaBiotechnologyCRISPR THERAPEUTICS AG
Mar 4, 202512,241,087Compositions and methods for differentiating stem cells into NK cellsBiotechnologyCRISPR THERAPEUTICS AG
Feb 18, 202512,227,763Methods and compositions for treating cancerBiotechnologyCRISPR THERAPEUTICS AG
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0381304METHODS AND COMPOSITIONS FOR IN VIVO EDITING OF STEM CELLSBiotechnologyCRISPR THERAPEUTICS AG
Dec 4, 20252025/0368959COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLSBiotechnologyCRISPR THERAPEUTICS AG
Oct 23, 20252025/0329417GUIDE DESIGN AND OFF-TARGET SEARCHESBiotechnologyCRISPR THERAPEUTICS AG
Oct 16, 20252025/0320477NOVEL RNA-PROGRAMMABLE ENDONUCLEASE SYSTEMS AND USES THEREOFBiotechnologyCRISPR THERAPEUTICS AG
Aug 28, 20252025/0269059RT EDITING COMPOSITIONS AND METHODSBiotechnologyCRISPR THERAPEUTICS AG
Aug 14, 20252025/0257320METHODS AND COMPOSITIONS FOR TREATING CANCERBiotechnologyCRISPR THERAPEUTICS AG
Jul 31, 20252025/0241954GENE-EDITED NATURAL KILLER CELLSBiotechnologyCRISPR THERAPEUTICS AG
Jul 24, 20252025/0235561MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSISBiotechnologyCRISPR THERAPEUTICS AG
Jul 17, 20252025/0228975METHODS AND COMPOSITIONS FOR TREATING LIPOPROTEIN-RELATED DISEASESPharmaceuticalsCRISPR THERAPEUTICS AG
Jun 5, 20252025/0179146GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCEBiotechnologyCRISPR THERAPEUTICS AG
What it applied for, 2024 to 2025: Biotechnology 22 · Pharmaceuticals 8 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CRSP · research, not advice